stock soars on obesity drug success, faces supply hurdles By Investing.com
Eli Lilly and Company (NYSE:), a global pharmaceutical giant with a market capitalization of $688 billion, has been making waves in the biopharmaceutical industry with its groundbreaking treatments for diabetes and obesity. As the company continues to expand its product portfolio and market presence, with impressive revenue growth of 27.4% over the last twelve months, investors and analysts are closely watching its performance and future prospects. According to InvestingPro analysis, the stock currently appears to be trading above its Fair Value, suggesting investors should carefully consider entry points. This comprehensive analysis delves into Eli Lilly’s current position, growth strategies, and the challenges it faces in an…
